2-chloro-6-(2-chloro-4-(6-methylpyrazin-2-yl)phenyl)-8-ethylpyrido[2,3-d]pyrimidin-7(8H)-one | 1433193-87-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-chloro-6-(2-chloro-4-(6-methylpyrazin-2-yl)phenyl)-8-ethylpyrido[2,3-d]pyrimidin-7(8H)-one
• 英文别名: 2-chloro-6-[2-chloro-4-(6-methylpyrazin-2-yl)phenyl]-8-ethylpyrido[2,3-d]pyrimidin-7-one
• CAS: 1433193-87-3
• 化学式: C₂₀H₁₅Cl₂N₅O
• 分子量: 412.278
• InChiKey: YOIRWLJDEIQBHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  71.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-chloro-6-(2-chloro-4-(6-methylpyrazin-2-yl)phenyl)-8-ethylpyrido[2,3-d]pyrimidin-7(8H)-one 、 N-甲基-4-(2-氨基乙基)哌啶 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 以49%的产率得到FRAX1036游离态
  参考文献：
  名称：

  An optimized synthesis of the potent and selective Pak1 inhibitor FRAX-1036

  摘要：

  FRAX-1036 is a p21-activated kinase I inhibitor of significant interest to cancer biologists yet no commercial providers or detailed procedures are available. In this Letter, we chronicle the optimized synthesis of FRAX-1036, one of the most specific Paid inhibitors known. We report a 65-fold increase in the overall yield of the seven-step sequence from 0.25% to 16.3%. Our improved route has provided gram quantities of FRAX-1036 for in vivo animal studies by the scientific community. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2015.12.059
• 作为产物：
  描述：

  2,4-二氯-5-嘧啶甲酸乙酯 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 2-chloro-6-(2-chloro-4-(6-methylpyrazin-2-yl)phenyl)-8-ethylpyrido[2,3-d]pyrimidin-7(8H)-one
  参考文献：
  名称：

  An optimized synthesis of the potent and selective Pak1 inhibitor FRAX-1036

  摘要：

  FRAX-1036 is a p21-activated kinase I inhibitor of significant interest to cancer biologists yet no commercial providers or detailed procedures are available. In this Letter, we chronicle the optimized synthesis of FRAX-1036, one of the most specific Paid inhibitors known. We report a 65-fold increase in the overall yield of the seven-step sequence from 0.25% to 16.3%. Our improved route has provided gram quantities of FRAX-1036 for in vivo animal studies by the scientific community. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2015.12.059

文献信息

• PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS
  申请人：AFRAXIS, INC.

  公开号：US20130116263A1

  公开（公告）日：2013-05-09

  Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of cell proliferative disorders and/or CNS disorders.

  本文提供了PAK抑制剂以及利用PAK抑制剂治疗细胞增殖性疾病和/或中枢神经系统疾病的方法。
• [EN] PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS<br/>[FR] INHIBITEURS DE PAK POUR LE TRAITEMENT DE TROUBLES DE PROLIFÉRATION CELLULAIRE
  申请人：AFRAXIS INC

  公开号：WO2013067423A1

  公开（公告）日：2013-05-10

  Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of cell proliferative disorders and/or CNS disorders.

  本文提供PAK抑制剂和利用PAK抑制剂治疗细胞增殖性疾病和/或中枢神经系统疾病的方法。
• PAK INHIBITORS FOR THE TREATMENT OF FRAGILE X SYNDROME
  申请人：AFRAXIS HOLDINGS, INC.

  公开号：US20150031693A1

  公开（公告）日：2015-01-29

  Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of Fragile X syndrome.

  本文提供PAK抑制剂以及利用PAK抑制剂治疗脆性X综合征的方法。
• [EN] PAK INHIBITORS FOR THE TREATMENT OF FRAGILE X SYNDROME<br/>[FR] INHIBITEURS DE LA PROTÉINE PAK POUR LE TRAITEMENT DU SYNDROME DE L'X FRAGILE
  申请人：AFRAXIS INC

  公开号：WO2013067434A1

  公开（公告）日：2013-05-10

  Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of Fragile X syndrome.
• An optimized synthesis of the potent and selective Pak1 inhibitor FRAX-1036
  作者：Alexander B. Koval、William M. Wuest

  DOI：10.1016/j.tetlet.2015.12.059

  日期：2016.1

  FRAX-1036 is a p21-activated kinase I inhibitor of significant interest to cancer biologists yet no commercial providers or detailed procedures are available. In this Letter, we chronicle the optimized synthesis of FRAX-1036, one of the most specific Paid inhibitors known. We report a 65-fold increase in the overall yield of the seven-step sequence from 0.25% to 16.3%. Our improved route has provided gram quantities of FRAX-1036 for in vivo animal studies by the scientific community. (C) 2015 Elsevier Ltd. All rights reserved.